Observational studyThe Lancet. Oncology2021

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Leticia Monin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.